Sapient provides multiomic biomarker discovery services based on high throughput mass spectrometry, bioinformatics, and access to a longitudinal human biology dataset. Sapient’s insights into dynamic biomarkers enable biopharma to make better decisions when prioritizing targets, patient populations, and drugs during discovery, development, clinical trials, or even following failed trials.
This multi-omics study, led by UPitt researchers, establishes causative linkages between key metabolites & PAH.
See how the partnership complements Sapient’s mass spectrometry-based proteomics & multi-omics services.
The paper details an innovative approach for assaying metabolic activities in intact human liver tissue.
